BIOMAT Database Logo BIOMAT Database Logo

Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. 2001

A I Veldkamp, and R P van Heeswijk, and J W Mulder, and P L Meenhorst, and G Schreij, and S van der Geest, and J M Lange, and J H Beijnen, and R M Hoetelmans
Departments of Pharmacy and Pharmacology and Internal Medicine, Slotervaart Hospital, Amsterdam, The Netherlands. apabg@slz.nl

OBJECTIVE To compare the steady state plasma pharmacokinetics of 1000 mg of saquinavir (SQV) in a soft-gel capsule (SGC) formulation in combination with 100 mg of ritonavir (RTV) (capsules) in a twice-daily dosing regimen in HIV-1-infected individuals with historical controls who used 400 mg of SQV in a hard-gel capsule (HGC) formulation in combination with 400 mg of RTV and to investigate the plasma pharmacokinetics of the 1000 mg/100 mg regimen after normal and high-fat breakfasts. METHODS Open-label, crossover, steady-state pharmacokinetic study. METHODS Six HIV-1-infected individuals who used either 1200 mg of SQV (SGC or HGC) three times daily or 400 mg twice daily in combination with 400 mg of RTV twice daily were included. Each patient was switched to 1000 mg of SQV SGC twice daily in combination with 100 mg of RTV twice daily. After 14 days, the patients came to the hospital for assessment of a pharmacokinetic profile during 12 hours. Patients were randomized to receive a high-fat (+/-45 g of fat) or normal (+/-20 g of fat) breakfast. After 7 days, a second pharmacokinetic profile was assessed after ingestion of the drugs with the alternate breakfast. A noncompartmental pharmacokinetic method was used to calculate the area under the plasma concentration versus time curve (AUC0-12h), the maximum plasma concentration (Cmax), the plasma trough concentration (C12h), and the elimination half-life in plasma (t1/2). The obtained pharmacokinetic parameters were compared with those of 12 patients using SQV HGC (400 mg twice daily) in combination with RTV (400 mg twice daily). RESULTS The median values of the pharmacokinetic parameters for SQV SGC (1000 mg twice daily, normal breakfast) were: AUC0-12h, 18.84 h*mg/L; Cmax, 3.66 mg/L; C12h, 0.40 mg/L; and t1/2, 3.0 hours. The median values of the pharmacokinetic parameters for SQV HGC (400 mg twice daily, normal breakfast) were: AUC0-12h, 6.99 h*mg/L; Cmax, 1.28 mg/L; C12h, 0.23 mg/L; and t1/2, 3.9 hours. The exposure to SQV in the dosing regimen of 1000 mg twice daily in combination with 100 mg of RTV twice daily was significantly higher than the exposure to SQV in a dosing regimen of 400 mg twice daily in combination with 400 mg of RTV twice daily. The pharmacokinetic parameters of SQV SGC in the dosing regimen of 1000 mg twice daily in combination with 100 mg of RTV twice daily were not significantly different after ingestion of a high-fat or normal breakfast (p >.35). CONCLUSIONS The combination of 1000 mg of SQV SGC twice daily and 100 mg of RTV twice daily resulted in a higher exposure to SQV compared with the exposure to SQV obtained when SQV is used in the 400 mg/400 mg twice-daily combination with RTV. In this small number of patients, no significant differences in exposure were seen after ingestion of either a normal or high-fat breakfast. From a pharmacokinetic perspective, the combination of 1000 mg of SQV SGC twice daily and 100 mg of RTV twice daily seems to be a good option for further clinical evaluation.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004041 Dietary Fats Fats present in food, especially in animal products such as meat, meat products, butter, ghee. They are present in lower amounts in nuts, seeds, and avocados. Fats, Dietary,Dietary Fat,Fat, Dietary
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

A I Veldkamp, and R P van Heeswijk, and J W Mulder, and P L Meenhorst, and G Schreij, and S van der Geest, and J M Lange, and J H Beijnen, and R M Hoetelmans
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
November 2004, Journal of acquired immune deficiency syndromes (1999),
A I Veldkamp, and R P van Heeswijk, and J W Mulder, and P L Meenhorst, and G Schreij, and S van der Geest, and J M Lange, and J H Beijnen, and R M Hoetelmans
Steady-state pharmacokinetics of lamivudine once-daily versus twice-daily dosing in Chinese HIV-infected patients.
January 2010, HIV clinical trials,
A I Veldkamp, and R P van Heeswijk, and J W Mulder, and P L Meenhorst, and G Schreij, and S van der Geest, and J M Lange, and J H Beijnen, and R M Hoetelmans
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.
June 2004, Antiviral therapy,
A I Veldkamp, and R P van Heeswijk, and J W Mulder, and P L Meenhorst, and G Schreij, and S van der Geest, and J M Lange, and J H Beijnen, and R M Hoetelmans
Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals.
January 2004, The new microbiologica,
A I Veldkamp, and R P van Heeswijk, and J W Mulder, and P L Meenhorst, and G Schreij, and S van der Geest, and J M Lange, and J H Beijnen, and R M Hoetelmans
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.
December 2008, The Journal of antimicrobial chemotherapy,
A I Veldkamp, and R P van Heeswijk, and J W Mulder, and P L Meenhorst, and G Schreij, and S van der Geest, and J M Lange, and J H Beijnen, and R M Hoetelmans
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
June 2001, British journal of clinical pharmacology,
A I Veldkamp, and R P van Heeswijk, and J W Mulder, and P L Meenhorst, and G Schreij, and S van der Geest, and J M Lange, and J H Beijnen, and R M Hoetelmans
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
January 2005, British journal of clinical pharmacology,
A I Veldkamp, and R P van Heeswijk, and J W Mulder, and P L Meenhorst, and G Schreij, and S van der Geest, and J M Lange, and J H Beijnen, and R M Hoetelmans
Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.
January 2006, Clinical drug investigation,
A I Veldkamp, and R P van Heeswijk, and J W Mulder, and P L Meenhorst, and G Schreij, and S van der Geest, and J M Lange, and J H Beijnen, and R M Hoetelmans
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
December 2011, Journal of acquired immune deficiency syndromes (1999),
A I Veldkamp, and R P van Heeswijk, and J W Mulder, and P L Meenhorst, and G Schreij, and S van der Geest, and J M Lange, and J H Beijnen, and R M Hoetelmans
Saquinavir with low-dose ritonavir twice daily.
January 2002, TreatmentUpdate,
Copied contents to your clipboard!